Eli Lilly Alzheimer's drug rejected by EU regulator Ruchika Sharma31 March 2025 5:20 PM ISTIndianapolis: Indianapolis-based pharmaceutical giant Eli Lilly has faced a setback as the European Union's drug regulator rejected its...
No major concerns raised by USFDA staff on Eli Lilly Alzheimer's drug Donanemab Ruchika Sharma7 Jun 2024 2:00 PM ISTLondon: FDA examination of trial data for Eli Lilly's investigational Alzheimer's drug Donanemab uncovered no red flags but did highlight safety...
USFDA advisers to weigh full nod for Eisai-Biogen Alzheimer's drug Leqembi Ruchika Sharma11 April 2023 10:00 AM ISTLeqembi belongs to a class of treatments that aim to slow the advance of the neurodegenerative disease by removing sticky clumps of the toxic protein...
USFDA rejects accelerated approval for Eli Lilly Alzheimer's drug Donanemab Ruchika Sharma20 Jan 2023 1:30 PM IST"I don't think it says anything negative about the drug. It was just a manifestation of the study design," said Dr. Ronald Petersen, an Alzheimer's...
Roche to stop all Gantenerumab studies in early Alzheimer's disease Ruchika Sharma2 Dec 2022 2:30 PM ISTRoche is still testing a different formulation of gantenerumab called trontinemab, designed to ferry the drug across the blood brain barrier -...
USFDA decision on Eisai, Biogen Alzheimer's drug due in January Ruchika Sharma6 July 2022 10:00 AM ISTEisai in March downsized its role in Aduhelm, but remains the leader in the 50-50 partnership's lecanemab program.
Biogen CEO to step down as drugmaker pulls back from Alzheimer's drug Aduhelm Ruchika Sharma4 May 2022 11:30 AM ISTBiogen said on Tuesday it was looking at "substantially" eliminating commercial infrastructure related to Aduhelm and plans for more cost cuts, in...
Biogen Alzheimer's drug: Former FDA adviser calls for wider probe into approval Ruchika Sharma21 July 2021 2:00 PM ISTNew Delhi: A federal probe of the U.S. Food and Drug Administration's approval of a controversial new Alzheimer's disease drug should look into why...
